Literature DB >> 6437430

Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.

J M Hows, A Mehta, L Ward, K Woods, R Perez, M Y Gordon, E C Gordon-Smith.   

Abstract

A prospective randomised study was carried out to compare the effect of mesna (2-mercaptoethane sulphonate sodium) with that of forced diuresis in preventing cyclophosphamide induced haemorrhagic cystitis in marrow transplant recipients. Sixty-one consecutive BMT recipients were randomised for treatment with forced diuresis or mesna. The incidence of macroscopic haematuria was significantly lower in the mesna treated group (chi 2 = 4.03, P less than 0.05). No specific side effects of mesna were detected. The lymphopenia induced by cyclophosphamide in the aplastic recipients was similar in the mesna and forced diuresis groups suggesting that mesna has no effect on the lymphocytotoxic activity of cyclophosphamide, although 6 out of 7 episodes of graft failure documented in the study occurred in mesna treated patients. As a result of this study our present policy is to use mesna in all BMT recipients but to continue careful documentation of the incidence of graft failure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437430      PMCID: PMC1977002          DOI: 10.1038/bjc.1984.252

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  HAEMORRHAGIC CYSTITIS AND CYCLOPHOSPHAMIDE.

Authors:  P GEORGE
Journal:  Lancet       Date:  1963-11-02       Impact factor: 79.321

2.  Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality.

Authors:  B M Camitta; E D Thomas; D G Nathan; G Santos; E C Gordon-Smith; R P Gale; J M Rappeport; R Storb
Journal:  Blood       Date:  1976-07       Impact factor: 22.113

3.  Prophylaxis of haemorrhagic cystitis due to cyclophosphamide-conditioning for bone marrow transplantation.

Authors:  H Link; V Neef; D Niethammer; K Wilms
Journal:  Blut       Date:  1981-11

4.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

5.  Cyclophosphamide cystitis--identification of acrolein as the causative agent.

Authors:  P J Cox
Journal:  Biochem Pharmacol       Date:  1979-07-01       Impact factor: 5.858

6.  Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle.

Authors:  R Storb; E D Thomas; P L Weiden; C D Buckner; R A Clift; A Fefer; L P Fernando; E R Giblett; B W Goodell; F L Johnson; K G Lerner; P E Neiman; J E Sanders
Journal:  Blood       Date:  1976-12       Impact factor: 22.113

7.  Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

Authors:  N Brock; J Stekar; J Pohl; U Niemeyer; G Scheffler
Journal:  Arzneimittelforschung       Date:  1979

8.  Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia.

Authors:  J M Hows; S Palmer; E C Gordon-Smith
Journal:  Transplantation       Date:  1982-04       Impact factor: 4.939

9.  Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A.

Authors:  J M Hows; P M Chipping; S Fairhead; J Smith; A Baughan; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

10.  Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Authors:  B M Bryant; M Jarman; H T Ford; I E Smith
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

View more
  5 in total

1.  Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?

Authors:  B Hellmich; I Kausch; C Doehn; D Jocham; K Holl-Ulrich; W L Gross
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

2.  CYCLOPHOSPHAMIDE INDUCED HAEMORRHAGIC CYSTITIS (A Case Report).

Authors:  P P Varma; D B Subba; P Madhoosudanan
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 3.  Evidence-Based Practice Recommendations for Hydration in Children and Adolescents With Cancer Receiving Intravenous Cyclophosphamide.

Authors:  Deborah Robinson; Ginny Schulz; Rachel Langley; Kevin Donze; Kari Winchester; Cheryl Rodgers
Journal:  J Pediatr Oncol Nurs       Date:  2014-05-05       Impact factor: 1.636

Review 4.  Management of pediatric and adult patients with medulloblastoma.

Authors:  Allison M Martin; Eric Raabe; Charles Eberhart; Kenneth J Cohen
Journal:  Curr Treat Options Oncol       Date:  2014-12

Review 5.  Drug-induced bladder and urinary disorders. Incidence, prevention and management.

Authors:  M J Drake; P M Nixon; J P Crew
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.